Strategy
BIOCORP’s strategic roadmap is based on three pillars: connected medical devices, digital solutions, and manufacturing. This structure ensures agility and innovation while aligning with Novo Nordisk’s processes and standards.
A growth strategy focused on high value connected devices
Under the umbrella brand Mallya®, BIOCORP is developing a range of connected devices for injection pens, deployed in various therapeutic areas. Expanding the Mallya platform is a key priority.
Following 𝗠𝗮𝗹𝗹𝘆𝗮ᴰ®, dedicated to diabetes care, BIOCORP is launching 𝗠𝗮𝗹𝗹𝘆𝗮ᴳ® in 2025, a connected device specifically designed for growth hormone injection pens. R&D continues in obesity, leveraging scientific and technological synergies with diabetes treatments.
Other avenues being explored include fertility and hemophilia, where innovative solutions are still greatly needed.
Development of digital solutions and complementary connected devices
Beyond manufactured devices, BIOCORP invests in digital innovation, including a mobile app to support treatment adherence and monitoring.
The company also develops new connected objects to enrich the therapeutic ecosystem such as smart syringes or diagnostic tools.
Manufacturing capacity serving innovation
BIOCORP’s production unit continues to meet custom requests from industrial partners. It leverages its tooling, molding, and plastic injection expertise to design and produce tailor-made solutions that meet industry standards and client expectations.